Pro Feature
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moCompany
Hetero
India - Hyderabad
MARAVIROC (maraviroc) by Hetero is chemokine co-receptor 5 antagonists [moa]. Approved for combination with other antiretroviral agents for the treatment of only ccr5-tropic hiv-1 infection in adults, older weighing at least 10 kg. First approved in 2023.
Drug data last refreshed 19h ago
Chemokine Co-receptor 5 Antagonists
CCR5 Co-receptor Antagonist
Worked on MARAVIROC at Hetero? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
The Canadian Maraviroc Randomized Controlled Trial To Augment Rehabilitation Outcomes After Stroke
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
Maraviroc to Augment Rehabilitation Outcomes After Stroke
Evaluating the Safety and Pharmacokinetics of Maraviroc in HIV-1-Exposed Infants at Risk of Acquiring HIV-1 Infection
Maraviroc Efficacy for Hepatitis C
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/mo